Search research articles
Contact Us
Filters
Showing results (11-20 of 125) with videos related to
Page
of 13
Sort By:
Current Oncology Reports
|
November 4, 2021
Current Role of Functional Imaging in the Management of Lymphoma
Bruce D Cheson, Michel Meignan
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
April 8, 2019
Time to Prepare for Risk Adaptation in Lymphoma by Standardizing Measurement of Metabolic Tumor Burden
Sally F Barrington, Michel Meignan
Blood
|
July 14, 2018
FDG-PET in PMBCL: which heterogeneity?
Michel Meignan, Anne-Ségolène Cottereau
Leukemia & Lymphoma
|
August 31, 2017
Interim PET in lymphoma: from Deauville to Peking criteria. On the road, again…
Michel Meignan, Anne-Ségolène Cottereau
International Journal of Radiation Biology
|
January 31, 2018
Monte Carlo simulations used to calculate the energy deposited in the coronary artery lumen as a function of iodine concentration and photon energy
Nora Hocine, Michel Meignan, Hélène Masset
The Oncologist
|
July 16, 2015
Imaging in Lymphoma: The Key Role of Fluorodeoxyglucose-Positron Emission Tomography
Michel Meignan, Martin Hutchings, Lawrence H Schwartz
The Lancet. Oncology
|
January 8, 2019
Does end-of-treatment FDG-PET improve outcomes in follicular lymphoma? - Authors' reply
Judith Trotman, Sally F Barrington, Michel Meignan, et al.
Leukemia & Lymphoma
|
November 17, 2010
Report on the Second International Workshop on interim positron emission tomography in lymphoma held in Menton, France, 8-9 April 2010
Michel Meignan, Andrea Gallamini, Corinne Haioun, et al.
Leukemia & Lymphoma
|
October 30, 2009
Interim 18F-fluorodeoxyglucose positron emission tomography in diffuse large B-cell lymphoma: qualitative or quantitative interpretation--where do we stand?
Michel Meignan, Emmanuel Itti, Andrea Gallamini, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
January 10, 2015
FDG PET/CT imaging as a biomarker in lymphoma
Michel Meignan, Emmanuel Itti, Andrea Gallamini, et al.
Page
of 13
Search research articles
Search
Showing results (11-20 of 125) with videos related to
Sort By:
Page
of 13
Current Oncology Reports
|
November 4, 2021
Current Role of Functional Imaging in the Management of Lymphoma
Bruce D Cheson, Michel Meignan
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
April 8, 2019
Time to Prepare for Risk Adaptation in Lymphoma by Standardizing Measurement of Metabolic Tumor Burden
Sally F Barrington, Michel Meignan
Blood
|
July 14, 2018
FDG-PET in PMBCL: which heterogeneity?
Michel Meignan, Anne-Ségolène Cottereau
Leukemia & Lymphoma
|
August 31, 2017
Interim PET in lymphoma: from Deauville to Peking criteria. On the road, again…
Michel Meignan, Anne-Ségolène Cottereau
International Journal of Radiation Biology
|
January 31, 2018
Monte Carlo simulations used to calculate the energy deposited in the coronary artery lumen as a function of iodine concentration and photon energy
Nora Hocine, Michel Meignan, Hélène Masset
The Oncologist
|
July 16, 2015
Imaging in Lymphoma: The Key Role of Fluorodeoxyglucose-Positron Emission Tomography
Michel Meignan, Martin Hutchings, Lawrence H Schwartz
The Lancet. Oncology
|
January 8, 2019
Does end-of-treatment FDG-PET improve outcomes in follicular lymphoma? - Authors' reply
Judith Trotman, Sally F Barrington, Michel Meignan, et al.
Leukemia & Lymphoma
|
November 17, 2010
Report on the Second International Workshop on interim positron emission tomography in lymphoma held in Menton, France, 8-9 April 2010
Michel Meignan, Andrea Gallamini, Corinne Haioun, et al.
Leukemia & Lymphoma
|
October 30, 2009
Interim 18F-fluorodeoxyglucose positron emission tomography in diffuse large B-cell lymphoma: qualitative or quantitative interpretation--where do we stand?
Michel Meignan, Emmanuel Itti, Andrea Gallamini, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
January 10, 2015
FDG PET/CT imaging as a biomarker in lymphoma
Michel Meignan, Emmanuel Itti, Andrea Gallamini, et al.
Page
of 13